Tag Archives: Vascular Biogenics

Vascular Biogenics (VBLT) Received its Third Buy in a Row

After Oppenheimer and H.C. Wainwright gave Vascular Biogenics (NASDAQ: VBLT) a Buy rating last month, the company received another Buy, this time from JonesTrading. Analyst Soumit Roy reiterated a Buy rating on Vascular Biogenics today and set a price target

Analysts’ Top Healthcare Picks: Vascular Biogenics (VBLT), Beam Therapeutics (BEAM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vascular Biogenics (VBLT – Research Report) and Beam Therapeutics (BEAM – Research Report) with bullish sentiments. Vascular Biogenics (VBLT) In a report

Roth Capital Keeps a Buy Rating on Vascular Biogenics (VBLT)

In a report issued on May 14, Jonathan Aschoff from Roth Capital reiterated a Buy rating on Vascular Biogenics (NASDAQ: VBLT), with a price target of $5.00. The company’s shares closed last Wednesday at $1.15. The word on The Street

Vascular Biogenics (VBLT) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Vascular Biogenics (VBLT – Research Report) today and set a price target of $2.50. The company’s shares closed last Monday at $1.19. According to TipRanks.com, DeGeeter is a 5-star analyst with

Oppenheimer Gives a Buy Rating to Vascular Biogenics (VBLT)

In a report released today, Kevin DeGeeter from Oppenheimer assigned a Buy rating to Vascular Biogenics (VBLT – Research Report), with a price target of $2.50. The company’s shares closed last Thursday at $1.21. According to TipRanks.com, DeGeeter is a

H.C. Wainwright Keeps Their Buy Rating on Vascular Biogenics (VBLT)

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Vascular Biogenics (VBLT – Research Report) on April 2 and set a price target of $3.00. The company’s shares closed last Friday at $1.16. According to TipRanks.com, Ramakanth has currently